

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except per share data)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2022	2021	2022	2021
Grant and collaboration revenue	\$ -	\$ 30	\$ 82	\$ 221
Operating expenses:				
Research and development	2,721	1,224	5,359	2,660
General and administrative	1,249	758	3,364	2,563
	<u>3,970</u>	<u>1,982</u>	<u>8,723</u>	<u>5,223</u>
Loss from operations	(3,970)	(1,952)	(8,641)	(5,002)
Other income (expense), net	2	1	4	175
Net loss	<u>\$ (3,968)</u>	<u>\$ (1,951)</u>	<u>\$ (8,637)</u>	<u>\$ (4,827)</u>
Loss per common share	<u>\$ (0.17)</u>	<u>\$ (0.31)</u>	<u>\$ (0.63)</u>	<u>\$ (0.80)</u>

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	Sep. 30, 2022	Dec. 31, 2021
Assets:		
Cash and cash equivalents	\$ 34,677	\$ 11,424
Other current assets	1,460	205
Total current assets	<u>36,137</u>	<u>11,629</u>
Property and other assets, net	2,433	168
Total assets	<u>\$ 38,570</u>	<u>\$ 11,797</u>
Liabilities and stockholders' equity		
Total liabilities	\$ 6,789	\$ 7,435
Stockholders' equity	31,781	4,362
Total liabilities and stockholders' equity	<u>\$ 38,570</u>	<u>\$ 11,797</u>
Common shares outstanding	26,334	6,382